GSK3B and hepatocellular carcinoma: In addition, we demonstrated that metformin repressed the AKT/GSK-3β pathway, the same signalling pathway activated by bFGF during EMT, to inhibit the migration and invasion of HCC cells, which supported the use of metformin in the clinical therapy of HCC.